Citigroup Issues Positive Forecast for Pfizer (NYSE:PFE) Stock Price

Pfizer (NYSE:PFE) had its price target lifted by investment analysts at Citigroup from $27.00 to $30.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Citigroup‘s target price suggests a potential downside of 2.58% from the stock’s current price.

Several other research analysts have also weighed in on PFE. HSBC increased their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, September 10th. Bank of America decreased their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. JPMorgan Chase & Co. raised their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. Finally, Royal Bank Of Canada boosted their price objective on shares of Pfizer from $25.00 to $28.00 and gave the company a “sector perform” rating in a report on Wednesday. Five analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $29.00.

Pfizer Trading Up 2.6%

NYSE:PFE traded up $0.79 on Wednesday, hitting $30.79. The stock had a trading volume of 46,664,040 shares, compared to its average volume of 39,771,121. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The stock has a market cap of $175.52 billion, a price-to-earnings ratio of 40.52, a PEG ratio of 2.08 and a beta of 0.31. The company has a fifty day moving average price of $28.64 and a two-hundred day moving average price of $26.84. Pfizer has a 1-year low of $23.62 and a 1-year high of $31.06.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.13. The business had revenue of $16.58 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.87 EPS. Equities research analysts expect that Pfizer will post 2.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pfizer

A number of institutional investors have recently modified their holdings of the company. TOWER TRUST & INVESTMENT Co boosted its position in shares of Pfizer by 1.9% during the 3rd quarter. TOWER TRUST & INVESTMENT Co now owns 19,322 shares of the biopharmaceutical company’s stock valued at $551,000 after purchasing an additional 357 shares in the last quarter. Angeles Wealth Management LLC raised its stake in Pfizer by 2.2% during the 2nd quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company’s stock valued at $410,000 after purchasing an additional 358 shares during the period. Manchester Financial Inc. lifted its stake in Pfizer by 2.9% in the 2nd quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 365 shares in the last quarter. Signature Equity Partners LLC boosted its holdings in shares of Pfizer by 22.9% during the third quarter. Signature Equity Partners LLC now owns 2,067 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 385 shares during the period. Finally, Delta Financial Advisors LLC boosted its stake in shares of Pfizer by 1.6% during the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after buying an additional 398 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat third-quarter estimates, reporting adjusted EPS of $0.87 and revenue of $16.58 billion. It raised 2026 guidance to $62–$64 billion in revenue and $2.95–$3.05 in adjusted EPS. Article: Pfizer: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Growth is increasingly coming from beyond COVID: non-COVID products grew 7% operationally, while launched and acquired products grew 32%. Eliquis, Padcev and other newer medicines helped support results, strengthening the case that Pfizer’s portfolio can offset pandemic-product weakness. Article: Non-COVID Portfolio Steps Up
• Positive Sentiment: Management is also pursuing growth in obesity medicines, with CEO Albert Bourla saying Pfizer aims to bring its past commercial experience to the weight-loss market. That opportunity could add longer-term upside, though it depends on pipeline and development progress. Article: Pfizer CEO Bourla Bets the Viagra Playbook Can Crack the Obesity Market
• Neutral Sentiment: Pfizer appointed company veteran Cecile Guegan permanent CFO after she served as interim CFO. The appointment provides continuity, but the announcement itself offers limited immediate evidence of a change in financial performance. Article: Pfizer Appoints Cecile Guegan as Chief Financial Officer
• Negative Sentiment: Quarterly revenue was nearly flat year over year as Comirnaty and Paxlovid sales declined sharply. This highlights the continuing challenge of replacing pandemic-era revenue and leaves Pfizer reliant on sustained growth from newer products. Article: Pfizer Q3 Revenue and Product Growth
• Negative Sentiment: Analyst views remain restrained: RBC raised its target to $28 but kept a “sector perform” rating, and J.P. Morgan assigned a “Hold.” RBC’s target is below the cited $30.75 share price, signaling limited upside in its assessment. Article: RBC Raises Pfizer Price Target

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.